Comirnaty (tozinameran - Pfizer/BIONTECH) for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. control
vs. placebo
vs. uncontrolled study
vs. vaccines
vs. Non replicating viral vector
vs. Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 2

table network network 2

display ongoing demontrated benefit only

click on circles to display study description...

C4591001 (Adolescents 12-25), 2021 NCT04368728

Comirnaty (tozinameran - Pfizer/BIONTECH) (n=1134) vs. placebo (n=1130)

randomized controlled trial

Studied treatment

BNT162b2
Two intramuscular injections of 30 μg of BNT162b2 21 days apart.

Control treatment

placebo
Two intramuscular injections of 30 μg of placebo (saline) 21 days apart.

Patients

COVID-19 prophylaxis (children)

Method

double-blind

multinational

Remark

powered by vis.js Network

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open